This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Think Research Gestione

Gestione criteri di controllo 2/4

Think Research Il CEO è Sachin Aggarwal, nominato in Jan2014, e ha un mandato di 10.25 anni. la retribuzione annua totale è CA$ 700.00K, composta da 57.1% di stipendio e 42.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 3.82% delle azioni della società, per un valore di CA$ 937.46K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 3.3 anni.

Informazioni chiave

Sachin Aggarwal

Amministratore delegato

CA$700.0k

Compenso totale

Percentuale dello stipendio del CEO	57.1%
Mandato del CEO	10.3yrs
Proprietà del CEO	3.8%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Think Research (CVE:THNK) Using Debt In A Risky Way?

Feb 10

Little Excitement Around Think Research Corporation's (CVE:THNK) Revenues As Shares Take 28% Pounding

Dec 18

Why Investors Shouldn't Be Surprised By Think Research Corporation's (CVE:THNK) 26% Share Price Plunge

Sep 06

Think Research Corporation (CVE:THNK) Shares Could Be 48% Below Their Intrinsic Value Estimate

Feb 28

Analysts Have Been Trimming Their Think Research Corporation (CVE:THNK) Price Target After Its Latest Report

Dec 01

Analysts Expect Breakeven For Think Research Corporation (CVE:THNK) Before Long

Mar 30

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Sachin Aggarwal rispetto agli utili di Think Research?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2023	n/a	n/a	-CA$15m
Jun 30 2023	n/a	n/a	-CA$18m
Mar 31 2023	n/a	n/a	-CA$23m
Dec 31 2022	CA$700k	CA$400k	-CA$26m
Sep 30 2022	n/a	n/a	-CA$28m
Jun 30 2022	n/a	n/a	-CA$32m
Mar 31 2022	n/a	n/a	-CA$30m
Dec 31 2021	CA$578k	CA$398k	-CA$29m
Sep 30 2021	n/a	n/a	-CA$35m
Jun 30 2021	n/a	n/a	-CA$24m
Mar 31 2021	n/a	n/a	-CA$22m
Dec 31 2020	CA$178k	CA$4k	-CA$18m

Compensazione vs Mercato: La retribuzione totale di Sachin ($USD 508.43K ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 170.32K ).

Compensazione vs guadagni: La retribuzione di Sachin è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Sachin Aggarwal

10.3yrs

Mandato

CA$700,000

Compensazione

Mr. Sachin Aggarwal has been Chief Executive Officer at Think Research Corporation since 2014 and serves as its Director since September 2010. He served as Chief Operating Officer at Think Research Corpora...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sachin Aggarwal	CEO & Director	10.3yrs	CA$700.00k	3.82% CA$ 937.5k
John Hayes	Chief Financial Officer	2yrs	CA$362.18k	0.094% CA$ 23.1k
Saurabh Mukhi	Chief Technology Officer	2.3yrs	CA$436.39k	0.85% CA$ 208.2k
Mark Sakamoto	Executive Vice President	12.6yrs	CA$437.50k	2.15% CA$ 526.8k
Patrick Craib	Chief Operating Officer	1.6yrs	Nessun dato	0.069% CA$ 16.8k
Michael Stewart	General Counsel & Corporate Secretary	3.3yrs	Nessun dato	0.21% CA$ 50.8k
Brynne Eaton-Auvaa	MD of Clinical Connectivity & Chief of Staff	2.3yrs	Nessun dato	0.20% CA$ 49.9k
Janet Kimura	MD & Executive VP of Clinical Content and Education	1.8yrs	Nessun dato	0.059% CA$ 14.5k
Anna Taylor	Managing Director of BioPharma Services	2.3yrs	Nessun dato	0.32% CA$ 77.6k

2.3yrs

Durata media

Gestione esperta: Il team dirigenziale di THNK è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sachin Aggarwal	CEO & Director	13.6yrs	CA$700.00k	3.82% CA$ 937.5k
Barry Reiter	Independent Director	3.3yrs	CA$50.00k	Nessun dato
Abe Schwartz	Independent Director	13.6yrs	Nessun dato	2.03% CA$ 498.3k
Cindy Gray	Independent Director	3.3yrs	CA$40.00k	0.078% CA$ 19.1k
Kirstine Stewart	Independent Director	3.3yrs	CA$50.00k	0.088% CA$ 21.6k
Richard Wells	Independent Director	3.3yrs	Nessun dato	0.020% CA$ 5.0k
Eric Hoskins	Independent Chairman of the Board	3.3yrs	CA$62.50k	Nessun dato
Jeffrey Orridge	Director	less than a year	Nessun dato	Nessun dato

3.3yrs

Durata media

61.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di THNK sono considerati esperti (durata media dell'incarico 3.3 anni).

This company listing is no longer active

Think Research Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Think Research Corporation, Annual General Meeting, Apr 04, 2024

Insufficient new directors

Think Research Corporation Appoints Jeffrey Orridge to Its Board of Directors

Think Research Corporation Announces Bridge Loan

Think Research Corporation, Annual General Meeting, Aug 11, 2023

High number of new directors

Recent updates

Healwell AI Inc. (TSX:AIDX) completed the acquisition of Bio Pharma Services Inc. from Think Research Corporation for CAD 15 million.

Healwell AI Inc. (TSX:AIDX) agreed to acquire 100% stake in Bio Pharma Services Inc. from Think Research Corporation for CAD 14.4 million.

Healwell AI Inc. (TSX:AIDX) agreed to acquire 100% stake in Bio Pharma Services Inc. from Think Research Corporation for CAD 14.4 million.

Beedie Capital completed the acquisition of remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 17.57 million.

Beedie Capital completed the acquisition of remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 17.57 million.

Think Research Corporation, Annual General Meeting, Apr 04, 2024

Beedie Capital entered into an arrangement agreement to acquire remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 25.58 million.

Beedie Capital entered into an arrangement agreement to acquire remaining 96.27551% stake in Think Research Corporation (TSXV : THNK) from shareholders for CAD 25.58 million.

Is Think Research (CVE:THNK) Using Debt In A Risky Way?

New major risk - Market cap size

Insufficient new directors

New major risk - Share price stability

Little Excitement Around Think Research Corporation's (CVE:THNK) Revenues As Shares Take 28% Pounding

New major risk - Market cap size

New minor risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Think Research Corporation to Report Q3, 2023 Results on Nov 27, 2023

Think Research Corporation Appoints Jeffrey Orridge to Its Board of Directors

Why Investors Shouldn't Be Surprised By Think Research Corporation's (CVE:THNK) 26% Share Price Plunge

Price target decreased by 14% to CA$0.73

Second quarter 2023 earnings: EPS exceeds analyst expectations

Think Research Corporation to Report Q2, 2023 Results on Aug 29, 2023

Think Research Corporation Announces Bridge Loan

First quarter 2023 earnings released: CA$0.047 loss per share (vs CA$0.11 loss in 1Q 2022)

Think Research Corporation, Annual General Meeting, Aug 11, 2023

Think Research Corporation to Report Q1, 2023 Results on May 29, 2023

Consensus EPS estimates fall by 17%

Full year 2022 earnings: EPS misses analyst expectations

Think Research Corporation (CVE:THNK) Shares Could Be 48% Below Their Intrinsic Value Estimate

Analysts Have Been Trimming Their Think Research Corporation (CVE:THNK) Price Target After Its Latest Report

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Think Research Corporation to Report Q3, 2022 Results on Nov 28, 2022

High number of new directors

Think Research Appoints John Hayes as Permanent Chief Financial Officer

Consensus revenue estimates fall by 11%

Price target decreased to CA$1.25

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Think Research Corporation to Report Q2, 2022 Results on Aug 29, 2022

Consensus forecasts updated

Think Research Corporation, Annual General Meeting, Aug 02, 2022

Think Research Corporation to Report Q1, 2022 Results on May 30, 2022

Now 26% undervalued after recent price drop

Now 24% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

High number of new directors

Think Research Corporation announced that it expects to receive CAD 25 million in funding from Beedie Capital

Price target decreased to CA$3.08

Think Research Corporation Announces Executive Changes

Think Research Launches Electronic Data Capture System for its Clinical Research Phase 1 Business, Bio Pharma Services Inc

Think Research Corporation Attests to Vendor Verification for Virtual Care in Ontario

CEO & Director recently sold CA$86k worth of stock

Consensus forecasts updated

High number of new directors

Chief Operating Officer Riyaz Lalani has left the company

Think Research Corporation (TSXV:THNK) completed the acquisition of BioPharma Services Inc. from Mahy Investments Ltd., Moske Investments Ltd., N & M Medical Enterprises Inc., Ola Kassim Medicine Professional Corporation and Kashima International Inc. for CAD 43.3 million.

Consensus revenue estimates increase to CA$45.4m

Think Research Corporation (TSXV:THNK) entered into a definitive agreement to acquire BioPharma Services Inc. for CAD 44.6 million.

Think Research Corporation Sees 140% Year-Over-Year Growth for eForms Electronic Data Capture Software in U.S. Post-Acute Care Market

Think Research Corporation Provides Earnings Guidance for the First Quarter Ended March 31, 2021

Analysts Expect Breakeven For Think Research Corporation (CVE:THNK) Before Long

Think Research Partners with Carerx to Deliver Virtualcare Telemedicine Software in Retirement Homes Across Canada

CareRx Corporation and Think Research Corporation Announces Their Canada-Wide Partnership to Deliver Virtual Healthcare to Seniors

Full year 2020 earnings released: CA$0.40 loss per share (vs CA$0.59 loss in FY 2019)

Think Research Corporation (TSXV:THNK) completed the acquisition of Clinic 360 for CAD 5.5 million.

Think Research Corporation (TSXV:THNK) acquired AirMed Trials Inc. for CAD 0.75 million.

Think Research Corporation (TSXV:THNK) entered into a share purchase agreement to acquire mdBriefCase Inc. from PCP GP, L.P. ,Jason Flowerday and others for CAD 24.9 million

Think Research Announces Appointment of Dr. Eric Hoskins to Board of Directors

Think Research Corporation (TSXV:THNK) agreed to acquire Clinic 360 for CAD 5.8 million.